What Researchers Did
Researchers reviewed the scientific evidence on how NMDA receptors in the brain respond to high-pressure conditions, looking at why divers and patients in hyperbaric chambers can experience nerve excitability problems.
What They Found
Both high-pressure neurological syndrome (HPNS, seen in divers below 11 ATA) and oxygen toxicity (seen at oxygen pressures above 2 ATA during HBOT) are caused by abnormal increases in nerve signaling activity. The key mechanism involves the GluN2A subunit of NMDA receptors, where high pressure removes a normally protective zinc-based block, leading to excessive electrical activity in neurons. This pathway is now identified as the main target for developing protective treatments.
What This Means for Canadian Patients
For patients undergoing HBOT, this research helps explain the rare but real risk of oxygen-related seizures or neurological side effects at high pressures. Understanding the mechanism may eventually lead to drugs that prevent these effects, making HBOT safer, especially for patients requiring higher pressures or longer sessions.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This is a mechanistic review with no clinical trial data; no interventions targeting the NMDA pathway for HPNS or HBOT toxicity have yet been tested in humans.